These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 3756945)
1. Etoposide and mitoguazone in refractory or recurrent non-Hodgkin's lymphomas of the unfavorable histologic subtypes. Winter JN; Gordon LI; Hauck WW; Variakojis D Cancer Treat Rep; 1986 Oct; 70(10):1243-4. PubMed ID: 3756945 [No Abstract] [Full Text] [Related]
2. Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma. O'Donnell MR; Forman SJ; Levine AM; Territo M; Farbstein MJ; Fahey JL; Gill P; Lazar G; Nademanee A; Neely S Cancer Treat Rep; 1987 Feb; 71(2):187-9. PubMed ID: 3802114 [TBL] [Abstract][Full Text] [Related]
3. Treatment of refractory non-Hodgkin's lymphomas of unfavorable histology with teniposide, cytarabine, and cisplatin. Tseng A; Jacobs C; Coleman CN; Horning SJ; Lewis BJ; Rosenberg SA Cancer Treat Rep; 1987 Jun; 71(6):659-60. PubMed ID: 3581106 [No Abstract] [Full Text] [Related]
4. [Treatment of aggressive non-Hodgkin's lymphoma in aged patients with a combination of methyl-GAG, etoposide and prednimustine]. Solal-Celigny P; Tertian G; Herrera A; Brousse N; Peuchmaur M Bull Cancer; 1990; 77(5):449-52. PubMed ID: 2400814 [TBL] [Abstract][Full Text] [Related]
5. Salvage combination chemotherapy with cisplatinum, etoposide and bleomycin in refractory non-Hodgkin's lymphomas. Comella P; Abate G; Di Finizio G; Fiore M; Zarrilli D J Chemother; 1989 Jul; 1(4 Suppl):1262-3. PubMed ID: 16312858 [No Abstract] [Full Text] [Related]
6. [A combination chemotherapy of mitoxantrone, etoposide, carboplatin, and prednisolone (MECP) in recurrent or refractory non-Hodgkin's lymphomas]. Matsuura Y; Nakamura H; Kogure K; Fukazawa M; Okuyama Y; Kawano E; Ishii A; Nishimura M; Hashimoto S; Oh H Gan To Kagaku Ryoho; 1994 Feb; 21(2):237-41. PubMed ID: 8311495 [TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients. Tirelli U; Zagonel V; Sorio R; Errante D; Talamini R; Carbone A; Monfardini S Semin Hematol; 1994 Apr; 31(2 Suppl 3):13-22. PubMed ID: 8073302 [No Abstract] [Full Text] [Related]
8. Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, vindesine, methotrexate with leucovorin rescue. Greek Lymphoma Research Group. Chemioterapia; 1987 Jun; 6(2 Suppl):721-3. PubMed ID: 3509941 [No Abstract] [Full Text] [Related]
9. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778 [TBL] [Abstract][Full Text] [Related]
10. Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone: a Southwest Oncology Group Pilot Study. Dana BW; Jones SE; Coltman C; Stuckey WJ Cancer Treat Rep; 1986 Feb; 70(2):291-2. PubMed ID: 3753898 [TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091 [TBL] [Abstract][Full Text] [Related]
12. A phase-II study with idarubicin, etoposide and prednisone (IVPP), in patients with refractory or early relapsed intermediate or high grade non-Hodgkin's lymphoma. Xiros N; Economopoulos T; Fountzilas G; Pavlidis N; Samantas E; Raptis S Haematologica; 1999 Feb; 84(2):189-90. PubMed ID: 10091424 [No Abstract] [Full Text] [Related]
13. [Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma]. Alekseeva IuA; Zaritskiĭ AIu; Medvedeva NV; Mikhaĭlova NB; Zubarovskaia LS; Afanas'ev BV Vopr Onkol; 2004; 50(6):726-8. PubMed ID: 15755073 [TBL] [Abstract][Full Text] [Related]
14. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). Zwick C; Birkmann J; Peter N; Bodenstein H; Fuchs R; Hänel M; Reiser M; Hensel M; Clemens M; Zeynalova S; Ziepert M; Pfreundschuh M; Ann Hematol; 2008 Sep; 87(9):717-26. PubMed ID: 18587579 [TBL] [Abstract][Full Text] [Related]
15. Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report. Goss PE; Burkes R; Rudinskas L; King M; Chow W; Myers R; Davidson M; Poldre P; Crump M; Sutton D Semin Hematol; 1994 Apr; 31(2 Suppl 3):23-9. PubMed ID: 8073303 [No Abstract] [Full Text] [Related]
16. Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, and bleomycin. Comella P; Abate G; Di Finizio G; Daponte A; Zarrilli D Cancer Chemother Pharmacol; 1990; 26(4):306-9. PubMed ID: 1695128 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma]. Bo LJ; Liang AB; Liu B; Chen YH; Wang F; Jin XP Ai Zheng; 2006 Dec; 25(12):1553-6. PubMed ID: 17166385 [TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas. Crown JP; Gulati S; Straus DJ; Kolitz J; Heelan R; O'Brien J; Lee BJ; Portlock C; Bertino J Invest New Drugs; 1991 May; 9(2):185-6. PubMed ID: 1874601 [TBL] [Abstract][Full Text] [Related]
20. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma. Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]